High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome

Xu,Jinsheng; Zhang,Junxia; Cui,Liwen; Zhang,Huiran; Zhang,Shenglei; Bai,Yaling

doi:10.3892/ol.2014.2196

High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome

Authors:
- Jinsheng Xu
- Junxia Zhang
- Liwen Cui
- Huiran Zhang
- Shenglei Zhang
- Yaling Bai
View Affiliations

Affiliations: Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: May 28, 2014 https://doi.org/10.3892/ol.2014.2196
Pages: 687-692

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The receptor tyrosine kinase, ephrin type-A receptor 2 (EphA2), is normally expressed at sites of cell‑to‑cell contact in adult epithelial tissues, however, recent studies have shown that it is also overexpressed in various types of epithelial carcinomas, with the greatest level of EphA2 expression observed in metastatic lesions. In the present study, the association between the expression of EphA2 and the outcome of RCC patients was assessed. The high expression level of EphA2 was identified by log‑rank test for a statistically significant prediction of the RCC outcome. In an overall multivariate analysis, the high expression level of EphA2 was identified as an independent predictor of RCC outcome. The length of survival of the patients with high EphA2 expression was shorter than that of the patients with a low level of expression (relative risk, 2.304; 95% CI, 1.102‑4.818; P=0.027). The analysis of the expression levels of EphA2 in tumor tissues may aid in the identification of the patient subgroup that are at a high risk of a poor disease outcome.

View Figures

View References

1	Remon J, Lianes P and Martínez S: Brain metastases from renal cell carcinoma. Should we change the current standard? Cancer Treat Rev. 38:249–257. 2012.
2	Salehipoor M, Khezri A, Behzad-Behbahani A, et al: Role of viruses in renal cell carcinoma. Saudi J Kidney Dis Transpl. 23:53–57. 2012.
3	Zhao P, Dai M, Chen W and Li N: Cancer trends in China. Jpn J Clin Oncol. 40:281–285. 2010.
4	Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 104:2323–2333. 2005.
5	Tran HT, Liu Y, Zurita AJ, et al: Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 13:827–837. 2012.
6	Nakamoto M and Bergemann AD: Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech. 59:58–67. 2002.
7	Andres AC, Reid HH, Zurcher G, Blaschke RJ, Albrecht D and Ziemiecki A: Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene. 9:1461–1467. 1994.
8	Holder N and Klein R: Eph receptors and ephrins: effectors of morphogenesis. Development. 126:2033–2044. 1999.
9	Zhang J and Hughes S: Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol. 208:453–461. 2006.
10	Lindberg RA and Hunter T: cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol. 10:6316–6324. 1990.
11	Bartley TD, Hunt RW, Welcher AA, et al: B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature. 368:558–560. 1994.
12	Holzman LB, Marks RM and Dixit VM: A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol. 10:5830–5838. 1990.
13	Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 41:275–280. 1999.
14	Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 61:2301–2306. 2001.
15	Kinch MS, Moore MB and Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 9:613–618. 2003.
16	Tandon M, Vemula SV, Sharma A, et al: EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med. 14:77–89. 2012.
17	Wittekind C: 2010 TNM system: on the 7th edition of TNM classification of malignant tumors. Pathologe. 31:331–332. 2010.(In German).
18	Singh M, Zaino RJ, Filiaci VJ and Leslie KK: Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 106:325–333. 2007.
19	Merritt WM, Lin YG, Han LY, et al: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 359:2641–2650. 2008.
20	Hou F, Yuan W, Huang J, et al: Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol. 29:2691–2700. 2012.
21	Liu Y, Zhang X, Qiu Y, et al: Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol. 137:761–769. 2011.
22	Yuan WJ, Ge J, Chen ZK, et al: Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci. 54:2410–2417. 2009.
23	Zantek ND, Walker-Daniels J, Stewart J, et al: MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res. 7:3640–3648. 2001.
24	Walker-Daniels J, Riese DJ II and Kinch MS: c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res. 1:79–87. 2002.
25	Kinch MS and Carles-Kinch K: Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis. 20:59–68. 2003.
26	Holm R, Knopp S, Suo Z, Tropè C and Nesland JM: Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis. J Clin Pathol. 60:1086–1091. 2007.
27	Jia Y, Zeng ZZ, Markwart SM, et al: Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res. 64:8674–8681. 2004.
28	Fang WB, Ireton RC, Zhuang G, Takahashi T, Reynolds A and Chen J: Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci. 121:358–368. 2008.
29	Brantley-Sieders DM, Zhuang G, Hicks D, et al: The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 118:64–78. 2008.